RJA
GH icon

Raymond James & Associates’s Guardant Health GH Stock Holding History

Raymond James & Associates’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$299K Buy
13,046
+1,769
+16% +$50.1K ﹤0.01% 3405
2024
Q2 		$326K Sell
11,277
-5,865
-34% -$137K ﹤0.01% 3332
2024
Q1 		$354K Sell
17,142
-94,604
-85% -$2.03M ﹤0.01% 3286
2023
Q4 		$3.02M Sell
111,746
-22,416
-17% -$588K ﹤0.01% 1839
2023
Q3 		$3.98M Buy
134,162
+9,770
+8% +$344K ﹤0.01% 1608
2023
Q2 		$4.45M Sell
124,392
-3,996
-3% -$115K ﹤0.01% 1557
2023
Q1 		$3.01M Sell
128,388
-3,076
-2% -$87.9K ﹤0.01% 1798
2022
Q4 		$3.58M Sell
131,464
-19,888
-13% -$910K ﹤0.01% 1649
2022
Q3 		$8.15M Sell
151,352
-6,572
-4% -$337K 0.01% 1072
2022
Q2 		$6.37M Sell
157,924
-7,817
-5% -$387K 0.01% 1244
2022
Q1 		$11M Sell
165,741
-25,254
-13% -$1.73M 0.01% 1013
2021
Q4 		$19.1M Sell
190,995
-8,772
-4% -$907K 0.02% 769
2021
Q3 		$25M Buy
199,767
+6,064
+3% +$720K 0.02% 594
2021
Q2 		$24.1M Sell
193,703
-3,177
-2% -$427K 0.02% 624
2021
Q1 		$30.1M Sell
196,880
-12,573
-6% -$1.9M 0.03% 484
2020
Q4 		$27M Sell
209,453
-1,956
-0.9% -$225K 0.03% 489
2020
Q3 		$23.6M Sell
211,409
-48,208
-19% -$4.41M 0.03% 475
2020
Q2 		$21.1M Buy
259,617
+3,918
+2% +$316K 0.03% 497
2020
Q1 		$17.8M Buy
255,699
+189,906
+289% +$14.6M 0.03% 498
2019
Q4 		$5.14M Buy
65,793
+12,423
+23% +$895K 0.01% 1225
2019
Q3 		$3.41M Buy
53,370
+461
+0.9% +$40.6K ﹤0.01% 1469
2019
Q2 		$4.57M Buy
52,909
+47,729
+921% +$3.65M 0.01% 1263
2019
Q1 		$397K Buy
+5,180
New +$287K ﹤0.01% 2816

Other funds holding GH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Raymond James & Associates's GH Position: Q3 2024 in Review

Raymond James & Associates increased its Guardant Health (GH) stake by 16% in Q3 2024, buying an estimated $50.1K and bringing the position to 13,046 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Raymond James & Associates first reported a position in GH in Q1 2019 and has held it in 23 quarters since. The position peaked at $30.1M in Q1 2021. 271 funds tracked by Wall St. Rank hold GH as of Q3 2024.

  • Raymond James & Associates held 13,046 shares of Guardant Health worth $299K as of Q3 2024.
  • Raymond James & Associates bought 1,769 Guardant Health shares in Q3 2024, an estimated $50.1K.
  • Guardant Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3405 holding.
  • Raymond James & Associates first reported a position in Guardant Health in Q1 2019 and has held it in 23 quarters since.
  • Raymond James & Associates's Guardant Health position peaked at $30.1M in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Guardant Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.